0001193125-26-224091
SEC filingCue Biopharma reported sharply higher collaboration revenue and improved operating income in Q1 FY2026, driven by a new partnership and reduced clinical trial and compensation costs — yet negative operating cash flow widened, and management explicitly states additional financing may not be available on acceptable terms or at all.
Effective January 10, 2026, Cue amended its Vivarium License to transition from private vivarium infrastructure to a shared, usage-based model — formalized in the Third Amendment. Under this arrangement, a 'slot' in the Shared Holding Room is defined as up to forty-four cages, with associated fees tied to actual cage usage, quarantine services performed at an off-site SmartLabs facility, and technical support. Capacity is limited, and advanced notice is recommended for increased usage. This structural shift reduces fixed-cost exposure but introduces variable cost uncertainty and operational dependency on third-party availability and pricing discretion.
Q1 FY2026 revenue totaled $5.7M, a 1250.6% increase over $421K in Q1 FY2025 — entirely attributable to collaboration revenue. The filing does not identify the partner or specify whether the amount reflects an upfront payment, milestone, or royalty stream. Operating income improved to -$5.4M (from -$12.3M YoY), a 56.5% year-over-year gain. This improvement was driven by decreases in clinical trial costs for the CUE-100 series and reductions in employee compensation — including stock-based compensation — partially offset by higher lab costs. The operating margin was -94.1%, reflecting the scale of investment relative to current revenue.
Net cash used in operating activities totaled -$10.9M, widening from -$8.2M in Q1 FY2025. This increase in cash outflow was primarily due to higher cash outflows from changes in research and development contract liabilities, accounts payable, and accrued expenses — partially offset by a decrease in net loss adjusted for non-cash expenses. Capital expenditures declined modestly to $121K (from $150K YoY), and free cash flow was -$11.1M. These trends underscore persistent liquidity pressure despite operational efficiencies.
The Company’s accumulated deficit, history of losses, negative cash flows from operations, future expected losses, and uncertain future capital resources raise substantial doubt about its ability to continue as a going concern within one year of the issuance date of these financial statements. Management has obtained and continues to pursue additional financing and cost-management initiatives to support future operations; however, it explicitly states that such funding may not be available on acceptable terms or at all. This candid assessment positions capital access — not scientific progress — as the immediate gating factor for advancing the pipeline.